论文部分内容阅读
[目的]评价α-胸腺肽对晚期结直肠癌化疗患者的细胞和体液免疫功能及生存期的影响。[方法]将60例晚期结直肠癌患者随机分为单纯化疗(30例)和α-胸腺肽联合化疗(30例),分别在化疗前和化疗4个疗程后第8d检测免疫功能,随访2年。[结果]与化疗前相比,晚期结肠癌患者接受4个化疗疗程后细胞免疫功能如CD3、CD4、NK比例均显著性降低(P<0.05),合并使用α-胸腺肽组患者细胞免疫功能均显著高于单纯化疗组。化疗4个疗程后第8d,加用α-胸腺肽组患者的IgG水平显著高于单纯化疗组患者(9.67g/L±1.62g/Lvs6.68g/L±0.93g/L,P<0.05)。单纯化疗组和联合组的PFS时间分别为3.7±0.21个月和4.2±0.41个月(P=0.020)。单纯化疗组和联合组的OS时间分别为9.6±0.82个月和11.6±0.89个月(P=0.037)。[结论]α-胸腺肽与化疗联用可显著改善晚期肿瘤化疗患者的机体免疫功能,并可延长患者的无病生存时间和总生存期。
[Objective] To evaluate the effect of α-thymosin on cellular and humoral immune function and survival in patients with advanced colorectal cancer. [Methods] Sixty patients with advanced colorectal cancer were randomly divided into chemotherapy alone (30 cases) and α-thymosin combined with chemotherapy (30 cases). The immune function was detected at the 8th day after chemotherapy and before chemotherapy for 2 years . [Results] Compared with those before chemotherapy, the cellular immune function such as CD3, CD4 and NK in patients with advanced colon cancer was significantly decreased after 4 cycles of chemotherapy (P <0.05) Significantly higher than chemotherapy alone group. The level of IgG in the patients treated with α-thymosin was significantly higher than that in patients treated with chemotherapy alone at the 8th day after chemotherapy (9.67g / L ± 1.62g / L vs 6.68g / L ± 0.93g / L, P <0.05). The PFS of the chemotherapy-alone group and the combination group were 3.7 ± 0.21 months and 4.2 ± 0.41 months, respectively (P = 0.020). OS time in the chemotherapy-alone and combination groups was 9.6 ± 0.82 months and 11.6 ± 0.89 months, respectively (P = 0.037). [Conclusion] The combination of α-thymosin and chemotherapy can significantly improve the immune function of patients with advanced cancer chemotherapy and prolong the disease-free survival and overall survival.